z-logo
open-access-imgOpen Access
Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results
Author(s) -
Kunihiko Wakamura,
Shinei Kudo,
Hideyuki Miyachi,
Kenta Kodama,
Seiko Hayashi,
Yasuharu Maeda,
Yushi Ogawa,
Yuta Kouyama,
Shinichi Kataoka,
Kazuki Kato,
Katsuro Ichimasa,
Masashi Misawa,
Yuichi Mori,
Toyoki Kudo,
Takemasa Hayashi,
Fumio Ishida,
Shogo Ohkoshi
Publication year - 2015
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2015.591
Subject(s) - asymptomatic , occult , molecular medicine , oncogene , colorectal cancer , medicine , cancer , gastroenterology , oncology , biology , pathology , cell cycle , alternative medicine
The immunochemical faecal occult blood test (iFOBT) is a simple, non-invasive colorectal cancer (CRC) screening method for reducing CRC-related mortality. However, the sensitivity of iFOBT is imperfect and certain colonic neoplasms that require removal may be missed. The aim of this study was to investigate the incidence and characteristics of CRC in asymptomatic, iFOBT-negative patients who underwent opportunistic screening. A total of 919 subclinical patients (276 iFOBT-positive and 643 iFOBT-negative) in the health screening program of our hospital underwent total colonoscopy (TCS) within 2 years after iFOBT. The patients were divided into an iFOBT-positive and an iFOBT-negative group and the TCS findings were compared between the two groups. Although the incidence of advanced neoplasia (CRC, high-grade dysplasia, adenoma sized ≥10 mm and tubulovillous adenoma) was significantly higher in the iFOBT-positive group, these lesions were also found in 6.3% of iFOBT-negative patients. The lesions tended to be proximally located and non-protruding. In conclusion, screening with iFOBT remains clinically significant. However, colonoscopy is indispensable for reducing the incidence and mortality of CRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom